The Evolving Landscape of Hypertrophic Cardiomyopathy: Clinical Assessment, Precision Therapies, and Emerging Strategies
Journal of Clinical Medicine · 01.11.2026 · 15 (21) · 8498
DOI: 10.3390/jcm15218498 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 01.11.2026. Verfasst von Alessandro Parodi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova, Via Giustiniani 2, 35100 Padua, Italy. Die Arbeit nennt 97 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Hypertrophic cardiomyopathy (HCM) is a genetically and phenotypically heterogeneous disease in which management requires integration of clinical assessment, cardiovascular physiology, multimodality imaging, functional evaluation, and arrhythmic risk. This review examines contemporary evaluation, risk stratification, and treatment of sarcomeric HCM across obstructive and non-obstructive phenotypes. In obstructive HCM, conventional negative inotropic therapy and septal reduction therapy remain established treatments, while cardiac myosin inhibitors have introduced a mechanism-based approach that improves left ventricular outflow tract obstruction, symptoms, and exercise capacity. Their role relative to septal reduction therapy should be individualized according to anatomy, hemodynamics, treatment burden, durability, and patient preference. In non-obstructive HCM, treatment remains largely symptom-directed, although recent trials of myosin inhibition have yielded divergent results, emphasizing the importance of appropriate patient selection. Emerging strategies targeting myocardial energetics and earlier disease stages may further expand treatment options. Gene-based therapies, including first-in-human MYBPC3 replacement, offer the possibility of targeting the underlying molecular defect but require careful evaluation of safety, durability, and timing. Overall, HCM remains a paradigmatic disease for physiology-driven, phenotype- and stage-specific care, increasingly complemented by molecularly targeted therapies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova, Via Giustiniani 2, 35100 Padua, Italy.
ORCID-Profile: Alessandro Parodi, Laura De Michieli, Marika Martini, Kalliopi Pilichou, Alberto Cipriani, Barbara Bauce
Zitieren
APA
Parodi, A., Baù, B., Piccolboni, G., Morat, N., De Michieli, L., Martini, M., Pilichou, K., Cipriani, A., Bauce, B., & Calore, C. (2026). The Evolving Landscape of Hypertrophic Cardiomyopathy: Clinical Assessment, Precision Therapies, and Emerging Strategies. Journal of Clinical Medicine, 15(21), 8498. https://doi.org/10.3390/jcm15218498
Vancouver
Parodi A, Baù B, Piccolboni G, Morat N, De Michieli L, Martini M, et al. The Evolving Landscape of Hypertrophic Cardiomyopathy: Clinical Assessment, Precision Therapies, and Emerging Strategies. Journal of Clinical Medicine. 2026;15(21):8498. doi:10.3390/jcm15218498
BibTeX
@article{Parodi2026,
author = {Parodi, Alessandro and Baù, Beatrice and Piccolboni, Giorgio and Morat, Nicola and De Michieli, Laura and Martini, Marika and Pilichou, Kalliopi and Cipriani, Alberto and Bauce, Barbara and Calore, Chiara},
title = {The Evolving Landscape of Hypertrophic Cardiomyopathy: Clinical Assessment, Precision Therapies, and Emerging Strategies},
journal = {Journal of Clinical Medicine},
year = {2026},
volume = {15},
number = {21},
pages = {8498},
doi = {10.3390/jcm15218498}
}
EUVIMED